
Annual report 2023
added 12-27-2025
Biophytis SA EBITDA 2011-2026 | BPTS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Biophytis SA
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -26.8 M | -13.9 M | -15.7 M | -13.9 M | -9.7 M | -7.77 M | -3.12 M | -659 K | -468 K | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -468 K | -26.8 M | -10.2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-143 M | $ 18.46 | -0.22 % | $ 2.72 B | ||
|
Amgen
AMGN
|
12.8 B | $ 344.63 | 0.8 % | $ 185 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
121 M | $ 70.06 | 1.05 % | $ 9.37 B | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Biogen
BIIB
|
673 M | $ 179.46 | -0.24 % | $ 26.1 B | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.7 | 3.85 % | $ 17 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
-35.2 M | $ 2.6 | -5.45 % | $ 146 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 9.78 | 0.93 % | $ 1.57 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.14 | -0.95 % | $ 7.55 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 4.32 | 7.67 % | $ 9.4 B | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Compugen Ltd.
CGEN
|
-34.6 M | $ 1.83 | -0.3 % | $ 164 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-44.7 M | $ 1.41 | - | $ 264 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
Celldex Therapeutics
CLDX
|
-192 M | $ 24.98 | 1.54 % | $ 1.61 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 226.97 | 0.38 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Cellectis S.A.
CLLS
|
-131 M | $ 3.86 | 1.72 % | $ 116 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 109.35 | -3.87 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
-99.9 M | - | - | $ 269 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.38 | 0.73 % | $ 352 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
138 M | $ 42.1 | 5.59 % | $ 4.35 B | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
196 M | $ 24.77 | 1.93 % | $ 2.93 B | ||
|
Cardiff Oncology
CRDF
|
-48.2 M | $ 1.7 | -3.14 % | $ 81 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
312 M | $ 13.96 | 2.01 % | $ 4.31 B | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
-1.3 M | $ 6.58 | - | $ 1.36 B |